Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 1 trial titled A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors. The study aims to evaluate the safety, tolerability, and efficacy of LY4101174 in patients with various advanced solid tumors, marking a significant step in cancer treatment research.
Intervention/Treatment: The study tests LY4101174, an antibody-drug conjugate administered intravenously, designed to target Nectin-4 in patients with advanced solid tumors, including bladder, breast, and lung cancers.
Study Design: This interventional study is non-randomized with a parallel assignment model. It involves no masking and focuses primarily on treatment. The study is divided into dose-escalation, dose-optimization, and dose-expansion phases to determine the optimal dosing strategy.
Study Timeline: The study began on January 26, 2024, with the latest update submitted on August 26, 2025. The study is expected to last up to four years, providing crucial data on LY4101174’s potential as a cancer treatment.
Market Implications: This update could positively influence Eli Lilly’s stock performance and investor sentiment, given the promising nature of LY4101174 in treating difficult cancers. As the study progresses, it could position Eli Lilly favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.